UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab

Revista española de enfermedades digestivas, 2017-02, Vol.109 (2), p.122-129

2017

Link zum Volltext

Verfügbarkeit prüfen

Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva

Revista española de enfermedades digestivas, 2016-04, Vol.108 (4), p.207-224

2016

Link zum Volltext

Verfügbarkeit prüfen

Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation

Digestive diseases and sciences, 2017-02, Vol.62 (2), p.481-490

2017

Link zum Volltext

Verfügbarkeit prüfen

Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients

Clinical gastroenterology and hepatology, 2020-01, Vol.18 (1), p.89-98

2020

Link zum Volltext

Verfügbarkeit prüfen

EUS-guided drainage of postsurgical pelvic abscesses using lumen-apposing metal stents

Revista española de enfermedades digestivas, 2019-07, Vol.111 (7), p.566-568

2019

Link zum Volltext

Verfügbarkeit prüfen

Bismuth quadruple regimen with tetracycline or doxycycline versus three‐in‐one single capsule as third‐line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp‐EuReg)

Helicobacter (Cambridge, Mass.), 2020-10, Vol.25 (5), p.e12722-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

Online social networks and inflammatory bowel disease

Revista española de enfermedades digestivas, 2018-05, Vol.110 (5), p.271

2018

Link zum Volltext

Verfügbarkeit prüfen

Online social networks and inflammatory bowel disease

Revista española de enfermedades digestivas, 2018-05, Vol.110 (5), p.271-273

2018

Link zum Volltext

Verfügbarkeit prüfen

Accuracy of GastroPanel for the diagnosis of atrophic gastritis

European journal of gastroenterology & hepatology, 2014-09, Vol.26 (9), p.941-948

2014

Link zum Volltext

Verfügbarkeit prüfen

Resources Utilization and Costs the Year Before and After Starting Treatment with Adalimumab in Crohn's Disease Patients

Inflammatory bowel diseases, 2015-07, Vol.21 (7), p.1631-1640

2015

Link zum Volltext

Verfügbarkeit prüfen

Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain : A Nationwide, Multicenter Study

The American journal of gastroenterology, 2009-01, Vol.104 (1), p.57-63

2009

Link zum Volltext

Verfügbarkeit prüfen

Malabsorption syndrome due to Strongyloides stercoralis associated with Loeffler syndrome in a 29-year-old woman

Gastroenterología y hepatología, 2006-06, Vol.29 (6), p.341-344

2006

Link zum Volltext

Verfügbarkeit prüfen

Rituximab-associated colitis

Gastroenterología y hepatología, 2019-04, Vol.42 (4), p.251

2019

Link zum Volltext

Verfügbarkeit prüfen

Colitis asociada a rituximab

Gastroenterología y hepatología, 2019-04, Vol.42 (4), p.251-252

2019

Link zum Volltext

Verfügbarkeit prüfen

Rituximab-associated colitis

Gastroenterología y Hepatología (English Edition), 2019-04, Vol.42 (4), p.251-252

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice

Gut, 2014-02, Vol.63 (2), p.244-249

2014

Link zum Volltext

Verfügbarkeit prüfen

Clinical status, quality of life, and work productivity in Crohns disease patients after one year of treatment with adalimumab

Revista española de enfermedades digestivas, 2016, Vol.109

2016

Link zum Volltext

Verfügbarkeit prüfen

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy

Gut, 2010-10, Vol.59 (10), p.1340-1346

2010

Link zum Volltext

Verfügbarkeit prüfen

Limited effectiveness with a 10‐day bismuth‐containing quadruple therapy (Pylera®) in third‐line recue treatment for Helicobacter pylori infection. A real‐life multicenter study

Helicobacter (Cambridge, Mass.), 2017-10, Vol.22 (5), p.n/a

2017

Link zum Volltext

Verfügbarkeit prüfen

European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain

Antibiotics (Basel), 2021-01, Vol.10 (1), p.13

2021

Link zum Volltext

Verfügbarkeit prüfen

Tu1107 Adalimumab Dose Escalation Is Effective for Managing Loss of Response in Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-789-S-789

2015

Link zum Volltext

Verfügbarkeit prüfen

Tu1335 European Registry on H. pylori Management (HP-EuReg) in Spain: Interim Analysis in First and Second Line Therapies

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S877-S877

2016

Link zum Volltext

Verfügbarkeit prüfen

Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3)

Journal of Crohn's and colitis, 2014-11, Vol.8 (11), p.1529-1538

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(31)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Gastroenterology & Hepatology
(15)
Humans
(15)
Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Adult
(12)
Female
(11)
Male
(11)
Middle Aged
(9)
Gastroenterology And Hepatology
(7)
Prospective Studies
(7)
Helicobacter Pylori
(6)
Young Adult
(6)
Antibiotics
(5)
Infectious Diseases
(5)
Treatment Outcome
(5)
Adalimumab
(4)
Aged
(4)
Bismuth
(4)
Clarithromycin
(4)
Helicobacter Infections - Drug Therapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab

Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva

Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation

Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients

EUS-guided drainage of postsurgical pelvic abscesses using lumen-apposing metal stents

Bismuth quadruple regimen with tetracycline or doxycycline versus three‐in‐one single capsule as third‐line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp‐EuReg)

Online social networks and inflammatory bowel disease

Online social networks and inflammatory bowel disease

Accuracy of GastroPanel for the diagnosis of atrophic gastritis

The Risk of Developing Disabling Crohn’s Disease: Validation of a Clinical Prediction Rule to Improve Treatment Decision Making

Resources Utilization and Costs the Year Before and After Starting Treatment with Adalimumab in Crohn's Disease Patients

Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain : A Nationwide, Multicenter Study

Malabsorption syndrome due to Strongyloides stercoralis associated with Loeffler syndrome in a 29-year-old woman

Rituximab-associated colitis

Colitis asociada a rituximab

Rituximab-associated colitis

Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg)

Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice

Clinical status, quality of life, and work productivity in Crohns disease patients after one year of treatment with adalimumab

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy

Limited effectiveness with a 10‐day bismuth‐containing quadruple therapy (Pylera®) in third‐line recue treatment for Helicobacter pylori infection. A real‐life multicenter study

European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain

Tu1107 Adalimumab Dose Escalation Is Effective for Managing Loss of Response in Ulcerative Colitis

Tu1335 European Registry on H. pylori Management (HP-EuReg) in Spain: Interim Analysis in First and Second Line Therapies

Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3)

Suchergebnisse filtern